By 2050, the number of adults over 65 years of age will be double the under-5 population,
and heavily concentrated in low-and middle-income countries. Population growth and …

The global burden of pneumococcal diseases is high, with young children and adults≥ 50
years of age at highest risk of infection. Two types of vaccine are available for the prevention …

Pneumococcal infections, including pneumonia and invasive disease, are major sources of
morbidity and mortality worldwide. Prevention of the first acquisition of S treptococcus …

Background Pneumococcal diseases cause substantial mortality, morbidity, and economic
burden. Evidence on data inputs for economic evaluations of interventions targeting …

Background Pneumococcal disease causes substantial morbidity and mortality, including
among adults. Adult pneumococcal vaccines help to prevent these burdens, but they are …

Introduction: Pneumococcal infection is a public health concern that disproportionately
affects the young, the elderly, and the immunocompromised. There is an open debate on the …

Background Patients with chronic obstructive pulmonary disease (COPD) are at elevated
risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was …

The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for
some adult groups and is being considered for wider use in many countries. In order to …

Introduction Several countries require manufacturers to present a budget impact analysis
(BIA), together with a cost-effectiveness analysis, to support national funding requests …

The mumps vaccine is not included in the national immunisation programme (NIP) of
approximately 80 countries including Japan. To investigate the vaccine's cost-effectiveness …